Literature DB >> 19524618

Pneumococcal carriage and acute otitis media induce serum antibodies to pneumococcal surface proteins CbpA and PhtD in children.

Birgit Simell1, Petra Ahokas, Mika Lahdenkari, Jan Poolman, Isabelle Henckaerts, Terhi M Kilpi, Helena Käyhty.   

Abstract

We assessed the development and role of serum anti-CbpA and -PhtD in early childhood in relation to pneumococcal exposure. Serum IgG concentrations to CbpA and PhtD were measured with enzyme immunoassay in serum samples collected at the ages of 6, 12, 18, and 24 months from 50 healthy children and from 50 adults. Furthermore, antibodies to CbpA, PhtD and the C-terminal fragment of PhtD (PhtD C) were measured in serum samples collected at 12 (N=286) and 18 months (N=259) to evaluate the risk of subsequent pneumococcal acute otitis media (AOM) in relation to antibody concentrations. The increase in anti-CbpA and -PhtD concentrations was related to prior pneumococcal exposure. At 12 and 18 months, in the risk model of pneumococcal AOM adjusted for prior pneumococcal AOM, higher concentrations of anti-CbpA, but not anti-PhtD, were associated with a lowered risk of subsequent pneumococcal AOM. In conclusion, pneumococcal exposure induces the development of serum anti-CbpA and -PhtD in early childhood. Anti-CbpA antibodies may play a role in the prevention of subsequent pneumococcal AOM during the second year of life.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524618     DOI: 10.1016/j.vaccine.2009.05.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Correlation of higher antibody levels to pneumococcal proteins with protection from pneumococcal acute otitis media but not protection from nasopharyngeal colonization in young children.

Authors:  Q Xu; J R Casey; A Almudevar; M E Pichichero
Journal:  Clin Microbiol Infect       Date:  2017-01-28       Impact factor: 8.067

2.  Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.

Authors:  Johan Berglund; Peter Vink; Fernanda Tavares Da Silva; Pascal Lestrate; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

3.  Co-colonization by Haemophilus influenzae with Streptococcus pneumoniae enhances pneumococcal-specific antibody response in young children.

Authors:  Qingfu Xu; Michael E Pichichero
Journal:  Vaccine       Date:  2013-12-16       Impact factor: 3.641

4.  Discovery of Immunodominant B Cell Epitopes within Surface Pneumococcal Virulence Proteins in Pediatric Patients with Invasive Pneumococcal Disease.

Authors:  Theano Lagousi; John Routsias; Christina Piperi; Athanassios Tsakris; George Chrousos; Maria Theodoridou; Vana Spoulou
Journal:  J Biol Chem       Date:  2015-09-22       Impact factor: 5.157

5.  Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children.

Authors:  Dabin Ren; Anthony L Almudevar; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Interaction of pneumococcal histidine triad proteins with human complement.

Authors:  Merit Melin; Emmanuel Di Paolo; Leena Tikkanen; Hanna Jarva; Cecile Neyt; Helena Käyhty; Seppo Meri; Jan Poolman; Merja Väkeväinen
Journal:  Infect Immun       Date:  2010-03-01       Impact factor: 3.441

7.  Antibody response to Streptococcus pneumoniae proteins PhtD, LytB, PcpA, PhtE and Ply after nasopharyngeal colonization and acute otitis media in children.

Authors:  Michael E Pichichero; Ravinder Kaur; Janet R Casey; Qingfu Xu; Anthony Almudevar; Martina Ochs
Journal:  Hum Vaccin Immunother       Date:  2012-04-12       Impact factor: 3.452

8.  Influence of age, social patterns and nasopharyngeal carriage on antibodies to three conserved pneumococcal surface proteins (PhtD, PcpA and PrtA) in healthy young children.

Authors:  A Hagerman; K M Posfay-Barbe; S Grillet; M M Ochs; R H Brookes; D Greenberg; N Givon-Lavi; R Dagan; C-A Siegrist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-18       Impact factor: 3.267

9.  Modeling specific antibody responses to natural immunization to predict a correlate of protection against infection before commencing a clinical vaccine trial.

Authors:  Anthony Almudevar; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 10.  Next generation protein based Streptococcus pneumoniae vaccines.

Authors:  Michael E Pichichero; M Nadeem Khan; Qingfu Xu
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.